Hexaell Biotech
Shanghai
About Hexaell Biotech
Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from Chinese Academy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $34.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2025)
- Website: hexaell.com
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/hexaell-biotech-125445 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.